SAMe Benefits For Depression, Osteoarthritis, Liver Disease Noted By AHRQ
This article was originally published in The Tan Sheet
Executive Summary
Dose escalation and risk benefit studies of SAMe for treatment of depression, osteoarthritis and liver disease are among the "promising" areas of future research involving the supplement ingredient identified by the Agency for Healthcare Research & Quality
You may also be interested in...
ODS Evidence-Based Review Program Recruits NCI Official
The National Institutes of Health's Office of Dietary Supplements will help stimulate and prioritize supplement research by commissioning several evidence-based reviews from the Agency for Healthcare Research & Quality
AHRQ Ephedra Evidence Report Targeted For August 2002 Release
An Agency for Healthcare Research & Quality report on the safety and efficacy of ephedra, commissioned by the National Institutes of Health, could be released as early as August 2002.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC